ArticleNPJ digital medicine2021
Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer's disease: the Altoida large cohort study.
Article in NPJ digital medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04701177 (Precision Medicine Initiative Against Alzheimer's Disease), which is not on this map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Precision Medicine Initiative Against Alzheimer's Disease (PMIAAD): Digitally-enhanced, Decentralized, Multi-omics, Observational Cohort
Who cites it
36 citing papers in PubMed, 56 citations in OpenAlex.
- Machine Learning-Based Cognitive Assessment With The Autonomous Cognitive Examination: Randomized Controlled Trial.Journal of medical Internet research · 2025Trial
- Article
- Artificial Intelligence and Digital Biomarkers for Early Detection and Monitoring of Neurological Disorders: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Review
- Discrete Cognitive Resolution in Alzheimer's Disease: Cross-Cohort Reanalysis of ADNI and NACC Longitudinal Data.bioRxiv : the preprint server for biology · 2026Article
- A framework of digital biomarkers for neurodegenerative diseases.Nature reviews bioengineering · 2026Article
- Research on Threshold Optimization and Variability-Based Digital Biomarker Approaches Through MMSE-Lifelog Multimodal Integrated Analysis from a Clinical Screening Perspective.Healthcare (Basel, Switzerland) · 2026Article
- Beyond traditional assessments of cognitive status: Exploring the potential of spatial navigation tasks.Behavior research methods · 2026Article
- Spatial navigation as a digital marker for clinically differentiating cognitive impairment severity.Communications medicine · 2026Article
- Listening for Alzheimer's clues: machine learning analysis of multidomain speech features for cognitive impairment screening.Frontiers in aging neuroscience · 2026Article
- Deep Learning for Classifying and Cognitive Profiling of Subcortical Vascular Cognitive Impairment.Cyborg and bionic systems (Washington, D.C.) · 2026Article
- Alzheimer's disease digital biomarkers multidimensional landscape and AI model scoping review.NPJ digital medicine · 2025Article
- Temporal Dynamics of Subtle Cognitive Change: Validation of a User-Friendly Multidomain Digital Assessment Using an Alcohol Challenge.Journal of medical Internet research · 2025Article
- Smartphone- and Tablet-Based Tools to Assess Cognition in Individuals With Preclinical Alzheimer Disease and Mild Cognitive Impairment: Scoping Review.Journal of medical Internet research · 2025Article
- Development of Neurodegenerative Disease Diagnosis and Monitoring from Traditional to Digital Biomarkers.Biosensors · 2025Review
- RADAR-AD: assessment of multiple remote monitoring technologies for early detection of Alzheimer's disease.Alzheimer's research & therapy · 2025Article
- A new method for identifying and evaluating depressive disorders in young people based on cognitive neurocomputing: an exploratory study.Frontiers in computational neuroscience · 2025Article
- Diets to promote healthy brain ageing.Nature reviews. Neurology · 2025Review
- Merging multimodal digital biomarkers into "Digital Neuro Fingerprints" for precision neurology in dementias: the promise of the right treatment for the right patient at the right time in the age of AI.Frontiers in digital health · 2025Article
- Identifying older adults at risk for dementia based on smartphone data obtained during a wayfinding task in the real world.PLOS digital health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 4 countries.
Funding
Abstract
Conventional neuropsychological assessments for Alzheimer's disease are burdensome and inaccurate at detecting mild cognitive impairment and predicting Alzheimer's disease risk. Altoida's Digital Neuro Signature (DNS), a longitudinal cognitive test consisting of two active digital biomarker metrics, alleviates these limitations. By comparison to conventional neuropsychological assessments, DNS results in faster evaluations (10 min vs 45-120 min), and generates higher test-retest in intraindividual assessment, as well as higher accuracy at detecting abnormal cognition. This study comparatively evaluates the performance of Altoida's DNS and conventional neuropsychological assessments in intraindividual assessments of cognition and function by means of two semi-naturalistic observational experiments with 525 participants in laboratory and clinical settings. The results show that DNS is consistently more sensitive than conventional neuropsychological assessments at capturing longitudinal individual-level change, both with respect to intraindividual variability and dispersion (intraindividual variability across multiple tests), across three participant groups: healthy controls, mild cognitive impairment, and Alzheimer's disease. Dispersion differences between DNS and conventional neuropsychological assessments were more pronounced with more advanced disease stages, and DNS-intraindividual variability was able to predict conversion from mild cognitive impairment to Alzheimer's disease. These findings are instrumental for patient monitoring and management, remote clinical trial assessment, and timely interventions, and will hopefully contribute to a better understanding of Alzheimer's disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.